Your session is about to expire
← Back to Search
Ropeginterferon Alfa-2B for Myelofibrosis
Study Summary
This trial looks at P1101 to treat patients with myelofibrosis. P1101 may help the body's natural response and slow the growth of myelofibrosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received any treatment for myelofibrosis.I have early stage mycosis fungoides with no treatment options left.I am in cohort 1 and have a high or intermediate-2 risk disease.I am currently breastfeeding.I am of childbearing age and not using birth control.My kidneys are functioning well.I had a heart attack less than 6 months ago or need ongoing treatment for heart failure.My spleen is enlarged due to myelofibrosis.I have intermediate-2 or high-risk myelofibrosis and cannot take or did not respond to ruxolitinib.I can take care of myself and am up and about more than half of my waking hours.I have had radiation treatment to my spleen within the last 3 months.I have moderate to severe numbness, tingling, or pain in my hands or feet.I am immunocompromised or HIV positive and on antiretroviral therapy.I have had a stem cell transplant before.I haven't had chemotherapy or radiation in the last 2 weeks.I do not have any other active cancer.I have been diagnosed with myelofibrosis according to WHO standards.
- Group 1: Treatment (PEG-proline-interferon alpha-2b)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What research has been undertaken to measure Quality-of-Life?
"Presently, 32 medicinal trials exploring Quality-of-Life Assessment are ongoing with 12 of them in the third phase. Although Buffalo, New york hosts many of these studies, there are 3489 other sites carrying out investigations related to Quality-of-Life Assessment."
Does Quality-of-Life Assessment pose any risks to participants?
"Quality-of-Life Assessment is ranked a 2 on our scale due to its Phase 2 designation, indicating that some safety data has been gathered but there are no studies yet supporting efficacy."
How is Quality-of-Life Assessment typically employed?
"Quality-of-Life Assessment is primarily employed to address malignancies and hematologic conditions. Additionally, the procedure has been found successful at ameliorating non-hodgkin's lymphoma, follicular lymphoma, hepatitis c virus (hcv) infection, and amino acid supplementation."
Is there an opportunity for new participants to join this research endeavor?
"The clinicaltrials.gov webpage suggests that this study, first posted on August 12th 2015 and last updated October 25th 2022, is no longer searching for participants. Nonetheless, there are 125 other trials actively recruiting at the moment."
How many participants are receiving the intervention in this trial?
"Currently, this experiment is not searching for participants. It was originally listed on August 12th 2015 and updated October 25th 2022. For those looking to participate in other studies relating to primary myelofibrosis there are 93 trials underway; 32 of which are Quality-of-Life Assessment related experiments that need volunteers."
Share this study with friends
Copy Link
Messenger